如何呈现患者和护理人员临床试验中的工作生产力损失结果? 混合方法是一种混合方法的方法
Jacynthe L'Heureux1, Helen McTaggart-Cowan2, Gary Johns3
1School of Population and Public Health, University of British Columbia; 2206 E Mall, Vancouver, British Columbia, V6T 1Z3, Canada.
Social science & medicine (1982)
|June 5, 2023
概括
患者和护理人员发现,工作生产力损失 (WPL) 结果在以简单的语言和视觉图表来表达,以天或成本来表达时,最容易理解. 建议在临床试验中标准化WPL结果报告.
科学领域:
- 健康研究成果研究结果
- 患者参与临床研究.
背景情况:
- 临床试验往往呈现复杂的数据,使得患者和护理人员难以理解工作生产力损失 (WPL) 的结果.
- 对WPL结果的有效沟通对于明智的决策和患者参与至关重要.
研究的目的:
- 确定向患者和护理人员展示WPL结果的最容易理解和最重要的方法.
- 确定在临床试验的背景下,哪些WPL结果被患者和护理人员认为具有意义.
主要方法:
- 采用了一种连续的混合方法设计,将以患者为导向的研究与一个患者合作伙伴结合起来.
- 与患者和护理人员进行了定性思考大声采访,随后对代表性的加拿大样本进行了定量调查.
- 统计分析包括使用通用估计方程进行线性和逻辑回归,并进行子组分析.
主要成果:
- 采访显示,他们更喜欢简短,简单,并以视觉形式表示WPL结果.
- 调查结果表明,以天数或成本来呈现的WPL显示出最高的可理解性和报告的重要性.
- 所有WPL结果通常被认为是重要的,可理解性与感知到的重要性有积极的关联.
结论:
- 通过使用易于理解的语言和视觉辅助工具,以天数和成本来呈现WPL结果,提高了患者和护理人员的理解和报告的重要性.
- 建议对临床试验中所有WPL结果的测量和报告进行标准化,以改善患者和护理人员的理解.
相关概念视频
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Kaplan-Meier Approach
197
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
197
Study Designs in Epidemiology
289
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
289
Hazard Ratio
168
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
168


